Carboplatin

Known as: CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum 
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two… (More)
National Institutes of Health

Related topics

Related topics

44 relations

Broader (2)

Antineoplastic AgentsCisplatin

Narrower (12)

BIC protocolCEO-PE protocolCIV protocolCarbo-MVE protocol
(More)
Bone Marrow DiseasesCAC protocolCTCb regimenCarboplat
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase…
BACKGROUND Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
BACKGROUND Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
 
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
PURPOSE Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer…
PURPOSE To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
PURPOSE Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
PURPOSE In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
BACKGROUND We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and… (More)
  • figure 1
  • figure 2
  • table 4
Is this relevant?
Highly Cited
1989
Highly Cited
1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A dosage formula has been derived from a retrospective analysis of carboplatin pharmacokinetics in 18 patients with pretreatment… (More)
Is this relevant?